- BATURA trial: Demonstrated the significant reduction of severe asthma exacerbation risk with as-needed albuterol-budesonide usage.
- Combination inhaler targets both bronchoconstriction and underlying inflammation.
- Safety profiles show comparable rates of adverse events.
- Implementation aligns with current Global Initiative for Asthma (GINA) recommendations.
- The virtual decentralized approach of the trial facilitated broader recruitment but led to a relatively high loss-to-follow-up rate.
Source: New England Journal of Medicine
